Search Results - "Penel, N."

Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study by Maio, M., Ascierto, P.A., Manzyuk, L., Motola-Kuba, D., Penel, N., Cassier, P.A., Bariani, G.M., De Jesus Acosta, A., Doi, T., Longo, F., Miller, W.H., Oh, D.-Y., Gottfried, M., Xu, L., Jin, F., Norwood, K., Marabelle, A.

“…BACKGROUNDPembrolizumab demonstrated durable antitumor activity in 233 patients with previously treated advanced microsatellite instability high (MSI-H) or…”
Get full text

Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study by Khoja, L., Atenafu, E.G., Suciu, S., Leyvraz, S., Sato, T., Marshall, E., Keilholz, U., Zimmer, L., Patel, S.P., Piperno-Neumann, S., Piulats, J., Kivelä, T.T., Pfoehler, C., Bhatia, S., Huppert, P., Van Iersel, L.B.J., De Vries, I.J.M., Penel, N., Vogl, T., Cheng, T., Fiorentini, G., Mouriaux, F., Tarhini, A., Patel, P.M., Carvajal, R., Joshua, A.M.

“…Despite the completion of numerous phase II studies, a standard of care treatment has yet to be defined for metastatic uveal melanoma (mUM). To determine…”
Get full text

An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG) by Kasper, B., Baumgarten, C., Garcia, J., Bonvalot, S., Haas, R., Haller, F., Hohenberger, P., Penel, N., Messiou, C., van der Graaf, W.T., Gronchi, A., Bauer, S., Blay, J.Y., van Coevorden, F., Dileo, P., Dürr, H.R., Fiore, M., Grünwald, V., Jones, R., Judson, I., Kettelhack, C., Kopeckova, K., Lazar, A., Lindner, L.H., Martin-Broto, J., Rutkowski, P., Stacchiotti, S., Stoeckle, E., Valverde, C., Verhoef, K., Wardelmann, E., Wartenberg, M.

“…Desmoid-type fibromatosis is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical…”
Get full text

Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO) by Valentin, T, Le Cesne, A, Ray-Coquard, I, Italiano, A, Decanter, G, Bompas, E, Isambert, N, Thariat, J, Linassier, C, Bertucci, F, Bay, J.O, Bellesoeur, A, Penel, N, Le Guellec, S, Filleron, T, Chevreau, C

“…Abstract Background Malignant peripheral nerve sheath tumors (MPNST) are a rare subtype of soft tissue sarcoma. They can arise in irradiated fields, in…”
Get full text

Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS) by Casali, P.G., Le Cesne, A., Velasco, A.P., Kotasek, D., Rutkowski, P., Hohenberger, P., Fumagalli, E., Judson, I.R., Italiano, A., Gelderblom, H., Penel, N., Hartmann, J.T., Duffaud, F., Goldstein, D., Martin-Broto, J., Gronchi, A., Wardelmann, E., Marréaud, S., Zalcberg, J.R., Litière, S., Blay, J.-Y.

“…In 2004, we started an intergroup randomized trial of adjuvant imatinib versus no further therapy after R0-R1 surgery in localized, high/intermediate-risk…”
Get full text

Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort by Italiano, A., Bessede, A., Pulido, M., Bompas, E., Piperno-Neumann, S., Chevreau, C., Penel, N., Bertucci, F., Toulmonde, M., Bellera, C., Guegan, J. P., Rey, C., Sautès-Fridman, C., Bougoüin, A., Cantarel, C., Kind, M., Spalato, M., Dadone-Montaudie, B., Le Loarer, F., Blay, J. Y., Fridman, W. H.

“…Immune checkpoint inhibitors (ICIs) show limited clinical activity in patients with advanced soft-tissue sarcomas (STSs). Retrospective analysis suggests that…”
Get full text

Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study by Le Cesne, A., Marec-Berard, P., Blay, J.-Y., Gaspar, N., Bertucci, F., Penel, N., Bompas, E., Cousin, S., Toulmonde, M., Bessede, A., Fridman, W.H., Sautes-Fridman, C., Kind, M., Le Loarer, F., Pulido, M., Italiano, A.

“…There are some lines of evidence suggesting a potential role of immunotherapy for treating patients with osteosarcomas. This was an open-label, multicentre,…”
Get full text

Why will there never be a randomized trial for NTRK-rearranged tumors? by Penel, N., Lebellec, L., Blay, J.-Y.

“…The optimal assessment of the risk-to-benefit ratio of a new treatment, particularly in oncology, has always been based on the results of prospective…”
Get full text

Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm—a position paper from the Italian and the French Sarcoma Group by Gronchi, A., Colombo, C., Le Péchoux, C., Dei Tos, A.P., Le Cesne, A., Marrari, A., Penel, N., Grignani, G., Blay, J.Y., Casali, P.G., Stoeckle, E., Gherlinzoni, F., Meeus, P., Mussi, C., Gouin, F., Duffaud, F., Fiore, M., Bonvalot, S.

“…Desmoid-type fibromatosis (DF) is a rare locally aggressive monoclonal proliferation of myofibroblasts lacking metastatic capacity. It may be observed in…”
Get full text

irRECIST and iRECIST: the devil is in the details by Le Lay, J., Jarraya, H., Lebellec, L., Penel, N.

Get full text

Targeting angiogenesis in advanced soft tissue sarcoma: tivozanib—hype or me-too? by Mir, O., Penel, N.

Get full text

Improving at a nationwide level the management of patients with sarcomas with an expert network by Blay, J.-Y., Penel, N., Gouin, F., Le Cesne, A., Toulmonde, M.

Get full text

Advanced chondrosarcomas: role of chemotherapy and survival by Italiano, A., Mir, O., Cioffi, A., Palmerini, E., Piperno-Neumann, S., Perrin, C., Chaigneau, L., Penel, N., Duffaud, F., Kurtz, J.E., Collard, O., Bertucci, F., Bompas, E., Le Cesne, A., Maki, R.G., Ray Coquard, I., Blay, J.Y.

“…There are limited data about the role of chemotherapy in patients with advanced chondrosarcomas. The medical charts of 180 patients with advanced…”
Get full text

Criteria for reference centers for sarcomas: volume but also long-term multidisciplinary organisation by Blay, J.-Y., Bonvalot, S., Gouin, F., Le Cesne, A., Penel, N.

Get full text

Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO) by Bompas, E., Le Cesne, A., Tresch-Bruneel, E., Lebellec, L., Laurence, V., Collard, O., Saada-Bouzid, E., Isambert, N., Blay, J.Y., Amela, E.Y., Salas, S., Chevreau, C., Bertucci, F., Italiano, A., Clisant, S., Penel, N.

“…There is no consensual treatment of locally advanced or metastatic chordomas. We conducted a multicenter, open-label, uncontrolled phase II trial of sorafenib…”
Get full text

Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): too few patients with matched treatment in Europe by Lamarca, A., Morfouace, M., Tejpar, S., Oliveira, J., Capela, A., Penel, N., Gennigens, C., Brasiuniene, B., Peron, J., Stevovic, A., Blay, J.-Y., Klümpen, H.-J.

Get full text

Lessons from three phase III trials assessing neoadjuvant treatment in sarcoma patients by Penel, N., Cordoba, A., Mathoulin-Pelissier, S.

Get full text

Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome by Penel, N., Italiano, A., Ray-Coquard, I., Chaigneau, L., Delcambre, C., Robin, Y.M., Bui, B., Bertucci, F., Isambert, N., Cupissol, D., Bompas, E., Bay, J.O., Duffaud, F., Guillemet, C., Blay, J.Y.

“…Angiosarcomas are a rare but aggressive form of soft tissue sarcoma. At metastatic stage, the clinical benefit of therapeutic intervention remains debatable…”
Get full text

A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial by Le Cesne, A., Blay, J.-Y., Cupissol, D., Italiano, A., Delcambre, C., Penel, N., Isambert, N., Chevreau, C., Bompas, E., Bertucci, F., Chaigneau, L., Piperno-Neumann, S., Salas, S., Rios, M., Guillemet, C., Bay, J.-O., Ray-Coquard, I., Haddag, L., Bonastre, J., Kapso, R., Fraslin, A., Bouvet, N., Mir, O., Foulon, S.

“…The French Sarcoma Group assessed the efficacy, safety, and quality of life (QoL) of trabectedin versus best supportive care (BSC) in patients with advanced…”
Get full text

Reply to letter to the editor “Bureaucracy or Streamlining the Rules in “Good Clinical Practice (GCP)” - Has Equipoise Occurred?” by H. K. Kotikonda, V. G. Jonnalagadda and S. R. Venna by Perez-Gracia, J.L., Penel, N., Calvo, E., Arkenau, H.T., Amaral, T., Grünwald, V., Sanmamed, M.F.

Get full text